Constance M. Yuan - Concepedia

Author

Constance M. Yuan

National Cancer Institute ORCID

Also Known As

C Yuan, C. M. YUAN, C. Yuan, Constance M Yuan, Constance M. YUAN, Constance M. Yuan, Constance Yuan, Hao-Wei Wang

258

Publications

14.6K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute National Institutes of Health Center for Cancer Research National Institutes of Health Clinical Center The University of Texas MD Anderson Cancer Center

About

Constance M. Yuan is an author at National Cancer Institute specializing in medicine, immunology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	28	6.1K
2	Health Sciences	8	8	3.1K
3	Public Health	2	2	140
4	Social Sciences	1	1	22
5	Allergy	1	1	1.3K

Constance M. Yuan

Publications

13.8K

Citations

H-Index

Page 1

	Year	Citations
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson, The Lancet T CellsT-regulatory CellImmunologyHematologyAutoimmunity	2014	2.9K
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy Terry J. Fry, Nirali N. Shah, Rimas J. Orentas, Nature Medicine AllergyAutoimmune DiseaseCd19-targeted Car ImmunotherapyAdaptive Immune SystemT-regulatory Cell	2017	1.3K
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia Yair Herishanu, Patricia Pérez‐Galán, Delong Liu, Blood	2010	811
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma Jennifer N. Brudno, Irina Marić, Steven D. Hartman, Journal of Clinical Oncology	2018	778
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia Waleed Haso, Daniel W. Lee, Nirali N. Shah, Blood	2012	576
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels James N. Kochenderfer, Robert Somerville, Tangying Lu, Journal of Clinical Oncology	2017	553
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial Nirali N. Shah, Steven L. Highfill, Haneen Shalabi, Journal of Clinical Oncology	2020	400
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial Mohammed Farooqui, Janet Valdez, Sabrina Martyr, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaTp53 AberrationsSingle-arm TrialMedicine	2014	365
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL Nirali N. Shah, Daniel W. Lee, Bonnie Yates, Journal of Clinical Oncology	2021	344
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia Inhye E. Ahn, Chingiz Underbayev, Adam Albitar, Blood	2017	336

Page 1